-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate

Reuters·03/26/2026 12:01:35

Please log in to view news